T1	Participants 485 729	174 MARS treatment sessions for 146 patients with liver failure and prothrombin time activity percentage (PTA) â‰¤ 40% were randomly divided into 2 groups: 92 MARS treatment sessions in the heparin-free group and 82 in the low-dose heparin group.
T2	Participants 290 382	subjects with liver failure, and to evaluate the safety of different anticoagulation methods
